Vallon Pharmaceuticals Inc (VLON) gains 0.42% for July 21

Equities Staff  |

Vallon Pharmaceuticals Inc (NASDAQ: VLON) shares gained 0.42%, or $0.02 per share, to close Wednesday at $4.83. After opening the day at $4.84, shares of Vallon fluctuated between $5.15 and $4.80. 26,682 shares traded hands a decrease from their 30 day average of 44,542. Wednesday's activity brought Vallon’s market cap to $32,905,998.

About Vallon Pharmaceuticals Inc

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

Visit Vallon Pharmaceuticals Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Vallon Pharmaceuticals Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Vallon Pharmaceuticals Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content